This is a preview of subscription content, log in via an institution to check access.
Notes
funded by AstraZeneca
Reference
Gilbert L, et al. Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy. Journal of Comparative Effectiveness Research : 30 Mar 2020. Available from: URL: https://doi.org/10.2217/cer-2020-0032
Rights and permissions
About this article
Cite this article
Cytotoxic chemotherapy increases costs but not survival in recurrent ovarian cancer in Canada. PharmacoEcon Outcomes News 851, 18 (2020). https://doi.org/10.1007/s40274-020-6741-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6741-5